Drug Profile
Research programme: inflammation therapeutics - Vernalis
Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Merck Serono; Vernalis
- Developer Vernalis
- Class
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in United Kingdom
- 01 Aug 2011 Preclinical trials in Inflammation in United Kingdom (unspecified route)